Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
- Report ID: GVR-3-68038-119-1
- Number of Report Pages: 100
- Format: PDF
- Historical Range: 2018 - 2023
- Forecast Period: 2025 - 2030
- Industry: Healthcare
Market Segmentation
- Idiopathic Pulmonary Fibrosis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Idiopathic Pulmonary Fibrosis Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
- Idiopathic Pulmonary Fibrosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Idiopathic Pulmonary Fibrosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- North America idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- North America idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- U.S.
- U.S. idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- U.S. idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- U.S. idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- U.S. idiopathic pulmonary fibrosis treatment market, by drug class
- Canada
- Canada idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Canada idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Canada idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Canada idiopathic pulmonary fibrosis treatment market, by drug class
- Mexico
- Mexico idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Mexico idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Mexico idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Mexico idiopathic pulmonary fibrosis treatment market, by drug class
- North America idiopathic pulmonary fibrosis treatment market, by drug class
- Europe
- Europe idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Europe idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Europe idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- UK
- UK idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- UK idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- UK idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- UK idiopathic pulmonary fibrosis treatment market, by drug class
- Germany
- Germany idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Germany idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Germany idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Germany idiopathic pulmonary fibrosis treatment market, by drug class
- France
- France idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- France idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- France idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- France idiopathic pulmonary fibrosis treatment market, by drug class
- Italy
- Italy idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Italy idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Italy idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Italy idiopathic pulmonary fibrosis treatment market, by drug class
- Spain
- Spain idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Spain idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Spain idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Spain idiopathic pulmonary fibrosis treatment market, by drug class
- Norway
- Norway idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Norway idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Norway idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Norway idiopathic pulmonary fibrosis treatment market, by drug class
- Denmark
- Denmark idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Denmark idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Denmark idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Denmark idiopathic pulmonary fibrosis treatment market, by drug class
- Sweden
- Sweden idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Sweden idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Sweden idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Sweden idiopathic pulmonary fibrosis treatment market, by drug class
- Europe idiopathic pulmonary fibrosis treatment market, by drug class
- Asia Pacific
- Asia Pacific idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Asia Pacific idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Asia Pacific idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Japan
- Japan idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Japan idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Japan idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Japan idiopathic pulmonary fibrosis treatment market, by drug class
- China
- China idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- China idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- China idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- China idiopathic pulmonary fibrosis treatment market, by drug class
- India
- India idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- India idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- India idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- India idiopathic pulmonary fibrosis treatment market, by drug class
- Australia
- Australia idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Australia idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Australia idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Australia idiopathic pulmonary fibrosis treatment market, by drug class
- South Korea
- South Korea idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- South Korea idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- South Korea idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- South Korea idiopathic pulmonary fibrosis treatment market, by drug class
- Thailand
- Thailand idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Thailand idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Thailand idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Thailand idiopathic pulmonary fibrosis treatment market, by drug class
- Asia Pacific idiopathic pulmonary fibrosis treatment market, by drug class
- Latin America
- Latin America idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Latin America idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Latin America idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Brazil
- Brazil idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Brazil idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Brazil idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Brazil idiopathic pulmonary fibrosis treatment market, by drug class
- Argentina
- Argentina idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Argentina idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Argentina idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Argentina idiopathic pulmonary fibrosis treatment market, by drug class
- Latin America idiopathic pulmonary fibrosis treatment market, by drug class
- MEA
- MEA idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- MEA idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- MEA idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- South Africa
- South Africa idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- South Africa idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- South Africa idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- South Africa idiopathic pulmonary fibrosis treatment market, by drug class
- Saudi Arabia
- Saudi Arabia idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Saudi Arabia idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Saudi Arabia idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Saudi Arabia idiopathic pulmonary fibrosis treatment market, by drug class
- UAE
- UAE idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- UAE idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- UAE idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- UAE idiopathic pulmonary fibrosis treatment market, by drug class
- Kuwait
- Kuwait idiopathic pulmonary fibrosis treatment market, by drug class
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
- Kuwait idiopathic pulmonary fibrosis treatment market, by route of administration
- Oral
- Injectable
- Kuwait idiopathic pulmonary fibrosis treatment market, by distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Kuwait idiopathic pulmonary fibrosis treatment market, by drug class
- MEA idiopathic pulmonary fibrosis treatment market, by drug class
- North America
Report content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2018 to 2030
- Market estimates and forecast for product segments up to 2030
- Regional market size and forecast for product segments up to 2030
- Market estimates and forecast for application segments up to 2030
- Regional market size and forecast for application segments up to 2030
- Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
